BioNTech counts on shift to cancer drugs after second quarter losses quadruple
Adds detail on oncology investment, Pfizer outlook
BERLIN, Aug 5 (Reuters) -Losses at German drugmaker BioNTech 22UAy.DE quadrupled in the second quarter from a year earlier, the company said on Monday, as it banks on a strategy shift towards new cancer treatments following a sharp drop-off in sales of its COVID-19 vaccine.
BioNTech reported a second-quarter net loss of 807.8 million euros ($885 million), versus a loss of 190.4 million a year earlier.
The company also saw a 23% drop in quarterly revenue to 128.7 million euros, mainly due to lower sales of its COVID-19 vaccines, whose development in partnership with U.S. partner Pfizer PFE.N and wide use during the pandemic made the small German biotech firm a household name.
"Our second quarter revenues correspond to the current demand of a seasonal endemic COVID-19 vaccine market," finance chief Jens Holstein said in a statement.
"Supported by our strong financial position, we will continue to focus on our long-term growth strategy throughout the remainder of the year," he added.
Some 90% of BioNTech's total research and development spending is going towards non-COVID related activities, mainly oncology and mRNA, the company said.
BioNTech is aiming for its first oncology launch in 2026.
Last week, Pfizer lifted its annual profit guidance as cancer treatments acquired through a $43 billion deal for Seagen and strong sales of its heart disease drug helped the company offset the post-pandemic slump in vaccine sales.
($1 = 0.9127 euros)
Writing by Rachel More, Editing by Miranda Murray and Susan Fenton
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.